



DISA Limited
(Company Registration No. 197501110N)
(Incorporated in the Republic of Singapore)

NEWS RELEASE:

DIGITAL LIFE LINE SECURES KEY HOSPITAL TRIAL FOR ITS AUTOMATED VISUAL ACUITY TEST DEVICE, SUPPORTING ITS EXPANSION INTO COMMUNITY HEALTHCARE

SINGAPORE – 20 November 2025 — DISA Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”), is pleased to announce that Digital Life Line Pte. Ltd. (“**DLL**”), a subsidiary of DiSa Digital Safety Pte. Ltd. that is a wholly owned subsidiary of the Company, has commenced a four-month clinical trial at Ng Teng Fong General Hospital (“**NTFGH**”). This trial will permit the Company’s flagship Automated Visual Acuity Test (“**AVAT**”) device to be tested in another independent acute hospital setting site, potentially allowing for the scaling of its technology across the broader healthcare ecosystem.

This strategic partnership follows the successful deployment and proven efficacy of AVAT devices at Singapore’s National University Hospital, where the technology demonstrated improvements in workflow efficiency, and reduction in patient wait times.

The trial at NTFGH is designed to demonstrate the AVAT system's utility and adaptability in a high-volume community hospital. Success in this environment is a key step for the Company's strategy to address the immense demand for ophthalmological services in mainstream healthcare settings. This move directly opens up a new market segment for DLL, beyond tertiary specialist centres.

"The trial at Ng Teng Fong General Hospital is the essential next step to demonstrate our technology’s core capability to make real-world impact. This partnership represents a tangible opportunity to replicate our success across the broader public health system, creating a recurring revenue stream," said Eddie Chng, CEO of Digital Life Line.

The AVAT device utilises proprietary optics and intuitive programming to automate the traditional visual acuity testing process, allowing patients to self-administer accurate eye exams with minimal supervision. This innovation frees up valuable time for healthcare professionals, enabling clinics to manage higher patient volumes and reduce operational costs.

Dr. Jamie Ng, Head of the Ophthalmology Department at Ng Teng Fong General Hospital, stated, "We are pleased to collaborate with Digital Life Line on this innovative trial. The integration of automated technologies like AVAT has the potential to significantly enhance our clinical efficiency and patient care experience. We look forward to evaluating its performance in our community-based setting and exploring its benefits for our patients and staff."

-----End-----

About DISA Limited (SGX Code - 532.SI / Bloomberg - DISA:SP / Reuters - DISA.SI)

DISA Limited is a publicly traded company on the Singapore Catalist Stock Exchange. Together with our subsidiaries, the Group focuses on pioneering and adopting the latest technology innovations to enhance outcomes, reduce costs, improve efficiencies within the healthcare and consumer industries.

Bringing scaled solutions that thrive in a changing world, we leverage on our strong in-house R&D capabilities to continuously pursue new innovations and disruptive technology (such as Artificial Intelligence, Internet of Things, etc.) for the digitalisation of product and services that optimises efficiency and quality standards in our targeted markets.

More information is available at www.disa.sg.

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms. Lee Khai Yinn, Registered Professional, SAC Capital Private Limited.

Address: 1 Robinson Road, #21-01 AIA Tower, Singapore 048542

Telephone number: +65 6232 3210